Dr. Picozzi details PANOVA-3, where TTFields with chemo showed significant survival gains in advanced pancreatic cancer.
Pancreatic
Advertisement
Bridging GI Oncology Care and Compassion: Dr. Joseph McCollom on Hope, Healing, and Human Connection
Dr. Joseph McCollom discusses his path to specialization in GI cancers and the pivotal role of palliative care in oncology.
Dr. Mahalingam shares preliminary results from the randomized phase 2 study of elraglusib with gemcitabine/nab-paclitaxel.
A post hoc analysis of the NAPOLI 3 trial offers insight into prolonged survival in mPDAC.
A therapy has shown a statistically significant OS benefit in patients with unresectable locally advanced pancreatic cancer.
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
The phase 3 NEOPAN study has shown that FOLFIRINOX can significantly improve PFS compared with gemcitabine.
Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.